ATE187336T1 - Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität - Google Patents

Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität

Info

Publication number
ATE187336T1
ATE187336T1 AT92917650T AT92917650T ATE187336T1 AT E187336 T1 ATE187336 T1 AT E187336T1 AT 92917650 T AT92917650 T AT 92917650T AT 92917650 T AT92917650 T AT 92917650T AT E187336 T1 ATE187336 T1 AT E187336T1
Authority
AT
Austria
Prior art keywords
interleukin
endotoxin
antagonist
analogue
treatment
Prior art date
Application number
AT92917650T
Other languages
English (en)
Inventor
Waal Malefyt Rene De
Maureen Howard
Di-Hwei Hsu
Hiroshi Ishida
Anne O'garra
Hergen Spits
Albert Zlotnik
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE187336T1 publication Critical patent/ATE187336T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
AT92917650T 1991-08-06 1992-08-06 Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität ATE187336T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74212991A 1991-08-06 1991-08-06

Publications (1)

Publication Number Publication Date
ATE187336T1 true ATE187336T1 (de) 1999-12-15

Family

ID=24983602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92917650T ATE187336T1 (de) 1991-08-06 1992-08-06 Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität

Country Status (17)

Country Link
EP (2) EP0600970B1 (de)
JP (3) JPH07502019A (de)
KR (1) KR100271197B1 (de)
AT (1) ATE187336T1 (de)
AU (1) AU678137B2 (de)
CA (1) CA2115060C (de)
CZ (1) CZ281796B6 (de)
DE (1) DE69230403T2 (de)
DK (1) DK0600970T3 (de)
ES (1) ES2138976T3 (de)
FI (1) FI940519A0 (de)
GR (1) GR3032167T3 (de)
HU (1) HU224437B1 (de)
NO (1) NO315409B1 (de)
PT (1) PT600970E (de)
SK (1) SK282947B6 (de)
WO (1) WO1993002693A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
EP0667789A1 (de) * 1992-09-18 1995-08-23 Schering Corporation Herstellung der immunozuständigkeit von helfer-t-zellen in hiv-infizierten patienten
CA2155109A1 (en) * 1993-02-01 1994-08-18 Daniel Abramowicz Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
IL110413A0 (en) * 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
MX9606537A (es) * 1994-07-05 1997-12-31 Steeno Res Group As Inmunomoduladores.
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
WO2002066069A1 (en) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedies for inflammatory/tumor diseases
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
AU2010323037B2 (en) 2009-11-30 2015-01-29 Biotest Ag Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
CA2899835A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
MX9203409A (es) * 1989-12-20 1992-07-01 Schering Corp Proteinas bcrfi como inhibidores de la gama interferona.

Also Published As

Publication number Publication date
FI940519A7 (fi) 1994-02-04
NO940370D0 (no) 1994-02-04
GR3032167T3 (en) 2000-04-27
NO315409B1 (no) 2003-09-01
AU2441192A (en) 1993-03-02
EP0541214A2 (de) 1993-05-12
WO1993002693A2 (en) 1993-02-18
NO940370L (no) 1994-02-04
FI940519L (fi) 1994-02-04
PT600970E (pt) 2000-05-31
CA2115060A1 (en) 1993-02-18
JP2004250454A (ja) 2004-09-09
CZ281796B6 (cs) 1997-02-12
FI940519A0 (fi) 1994-02-04
JPH07502019A (ja) 1995-03-02
EP0600970B1 (de) 1999-12-08
JP2008013573A (ja) 2008-01-24
WO1993002693A3 (en) 1993-07-22
SK282947B6 (sk) 2003-01-09
DE69230403D1 (de) 2000-01-13
DE69230403T2 (de) 2000-05-11
SK12994A3 (en) 1994-12-07
AU678137B2 (en) 1997-05-22
HU9400314D0 (en) 1994-05-30
CZ24394A3 (en) 1995-01-18
HUT66865A (en) 1995-01-30
ES2138976T3 (es) 2000-02-01
KR100271197B1 (ko) 2000-11-01
CA2115060C (en) 2003-05-06
DK0600970T3 (da) 2000-05-29
HU224437B1 (hu) 2005-09-28
EP0541214A3 (en) 1993-09-08
EP0600970A1 (de) 1994-06-15

Similar Documents

Publication Publication Date Title
ATE384703T1 (de) Piperazinyl-substituierte phenylpyrimidinderivative zur behandlung oder vorbeugung von zns erkrankungen
DE69127437D1 (de) Stickoxide zur gewichtsreduktion
DE69324859D1 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
EP0735870A4 (de) Verwendung von phospholipase-a2-inhibitoren zur behandlung der alzheimer-krankheit
LV10048A (lv) Lidzeklis slimibu arstesanai un ta iegusanas process
DE69435270D1 (de) Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69214610D1 (de) Verfahren zur Behandlung von Erdgas
FI943396L (fi) Synteettisiä peptidejä bakteeriendotoksiinien myrkyttömäksi tekemistä ja septisen shokin hoitoa varten
BG60249B1 (bg) Тиазолово съединение за лечение на язви
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69230403D1 (de) Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität
ATE152725T1 (de) Silylierte acetylcholinesterase inhibitoren
DE69405711D1 (de) Behandlung von rueckstandsoel
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69300321D1 (de) Behandlung neurodegenerativer Erkrankungen.
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
FI933739A0 (fi) Foerfarande och komposition foer kontrollering av mikroorganismtillvaext
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE59209484D1 (de) Verfahren zur reinigung von gebrauchten schmierölen
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69232918D1 (de) Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität
DE69215191D1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee